KOSDAQBiotech & Pharma106190

High Tech Pharm

₩7,710▼ 0.39%2026-11-18 close
Market Cap
₩82B
Turnover
₩76,562,480
Volume
9.9K
Shares out.
10.6M
PER
11.2×
PBR
0.6×
EPS
₩692
Dividend Yield
1.94%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩150 per share · Prices as of the 2026-11-18 close

01

Report overview

Export-focused carbapenem API maker; utilization recovery in focus

High Tech Pharm's operating profit fell 71.8% year on year in the third quarter of 2026 and the company swung to a net loss attributable to controlling shareholders, leaving production normalization and regulatory approval gains as the key tests.

  1. 1

    Exports were 99.95% of 2025 revenue of KRW 70.2 billion, with Europe at 87.37%, so regional concentration is high.

  2. 2

    Operating profit fell 17.4% to KRW 12.9 billion in 2025, and the operating margin slipped from 20.1% to 18.3%.

  3. 3

    Third-quarter 2026 revenue rose 4.6% year on year to KRW 18.7 billion, but operating profit fell 71.8% to KRW 1.1 billion and the company posted a net loss attributable to controlling shareholders of KRW 774 million.

  4. 4

    According to first-quarter 2026 IR materials, utilization at the Chungju and Daeso plants stayed at 62.7% and 62.9%.

  5. 5

    On October 2, 2026, a finished product using its ertapenem ingredient received Swiss marketing approval, adding to its regulatory footprint.

02

Business structure

High Tech Pharm, founded in 1998 and listed on KOSDAQ, is an active pharmaceutical ingredient (API) maker whose core products are carbapenem antibiotic APIs, including imipenem and ertapenem. Exports accounted for 99.95% of 2025 revenue of KRW 70.2 billion, and Europe alone made up 87.37%.

By product line, carbapenem sales were KRW 66.9 billion, or 95.3% of the total, while cephalosporin sales were about KRW 1.8 billion. Some press reports put the carbapenem share at 86.4%, so the figure should be checked against the full annual report.

ACS Dobfar, an Italian pharmaceutical company, accounted for 87.4% of 2025 revenue and was the largest shareholder with 45.19% of the shares in a filing dated March 30, 2026.

Finished products using the company's ertapenem have won approvals in the United States, the EU, Saudi Arabia, the UAE and several Southeast Asian countries. A global pharmaceutical company's carbapenem combination antibiotic that uses the company's ingredient was approved by the FDA and the European Union in 2025.

Canada, Argentina and three Balkan countries added approvals in 2026. On the competitive side, the annual report cites aggressive price competition and dumping by Chinese manufacturers as a major external factor.

Both customer and product concentration are high, so the key structural question is how far approvals in regulated markets translate into new buyers and higher volumes.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17.9B₩3.9B21.9%
2025Q4₩14B₩3.2B22.6%
2026Q1₩14.1B-₩1.1B−7.8%
2026Q2₩23.4B₩6.3B26.9%
2026Q3₩18.7B₩1.1B5.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩102.9B₩4.9B₩5.9B4.8%5.9%32.3%
2023₩76.8B₩10.1B₩8.1B13.1%7.5%26.2%
2024₩77.5B₩15.6B₩13.7B20.1%11.4%17.0%
2025₩70.2B₩12.9B₩11.5B18.3%8.8%10.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Revenue went from KRW 102.9 billion in 2022 to KRW 76.8 billion in 2023, a 25.4% decline, then rose 1.0% to KRW 77.5 billion in 2024 before falling 9.5% to KRW 70.2 billion in 2025, which is the smallest year in the 2022–2025 period; 2022 was the largest.

Operating profit rose from KRW 4.93 billion in 2022 to KRW 10.1 billion in 2023 (up 104.8%) and KRW 15.6 billion in 2024 (up 54.2%), making 2024 the largest year, before falling 17.4% to KRW 12.9 billion in 2025.

The operating margin climbed from 4.8% in 2022 to 13.1% in 2023 and 20.1% in 2024, then eased to 18.3% in 2025.

Profit attributable to controlling shareholders grew from KRW 5.87 billion in 2022 to KRW 13.7 billion in 2024 (up 69.8% year on year) and then declined 16.3% to KRW 11.5 billion in 2025; net profit including non-controlling interests was reported at the same amounts in each year.

The company's annual report points to a roughly 40-day production gap at year-end 2025 linked to equipment investment at the Chungju and Daeso synthesis buildings, supply instability after an explosion at an overseas intermediate-material supplier, and dumping by Chinese competitors.

The balance sheet strengthened: the debt ratio fell from 32.3% in 2022 to 10.0% in 2025, with total equity of KRW 130.7 billion, all attributable to controlling shareholders, and total liabilities of KRW 13 billion at year-end 2025.

Operating cash flow moved from negative KRW 3.7 billion in 2022 to KRW 2.91 billion in 2023, KRW 14.7 billion in 2024 and KRW 17 billion in 2025, which exceeded profit attributable to controlling shareholders of KRW 11.5 billion.

Quarterly, the third quarter of 2025 showed revenue of KRW 17.9 billion, operating profit of KRW 3.91 billion and controlling-shareholder profit of KRW 3.79 billion; the fourth quarter brought revenue of KRW 14 billion (down 21.4% from the prior quarter) and operating profit of KRW 3.17 billion.

In the first quarter of 2026 revenue was KRW 14.1 billion with an operating loss of KRW 1.1 billion and a controlling-shareholder net loss of KRW 267 million, a swing into loss that the company attributed to temporary items including equipment maintenance and stock-compensation costs.

The second quarter of 2026 returned to profit, with revenue of KRW 23.4 billion (up 65.5% from the prior quarter), operating profit of KRW 6.29 billion and controlling-shareholder profit of KRW 5.25 billion.

The third quarter of 2026 showed revenue of KRW 18.7 billion (up 4.6% year on year), operating profit of KRW 1.1 billion (down 71.8% year on year) and a controlling-shareholder net loss of KRW 774 million, a swing into loss year on year.

Controlling-shareholder profit for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 7.36 billion.

05

Industry analysis

Carbapenem antibiotic APIs are produced at scale by few companies in Korea, according to industry assessments. One industry official described High Tech Pharm as a rare carbapenem API specialist in Korea with technological strength and competitiveness in regulated markets.

Demand is linked to the sales and approvals of finished-product customers, so their tender and approval outcomes shape order volumes. On the supply side, the annual report names excessive price competition and dumping by Chinese manufacturers as an external factor behind the 2025 decline.

On the raw-material side, an explosion at an overseas intermediate supplier unsettled supply. In the regulatory environment, expansion of regulated markets based on FDA and EU GMP standards is presented as the company's core growth axis.

A 2026 press report attributed a joint earnings decline among API makers to drug price reform and a strong-dollar environment, and with exports close to 100% of sales, exchange rates and drug pricing feed directly into revenue translation and selling prices.

Against peers, the company's differentiation is that its carbapenem production track record and regulated-market approval history are building together. As long as price competition from Chinese manufacturers persists, the industry requires both price defense and a recovery in utilization.

06

Outlook

At the general shareholders' meeting on March 20, 2026, the 28th-term financial statements were approved and a year-end cash dividend was resolved. A disclosure dated April 27, 2026 named Chahn Hyun-jun as CEO effective May 1, 2026, and former CEO Kim Jeong-su remains as an inside director.

The new CEO has set production stabilization and profit recovery as core tasks. Utilization in the first quarter of 2026 stayed in the 60% range, at 62.7% in Chungju and 62.9% in Daeso, and the company said the first-quarter loss reflected temporary items including equipment maintenance and stock-compensation costs.

Whether the return to profit in the second quarter of 2026 was sustained alongside better utilization, and whether the third-quarter decline in operating profit is explained by temporary factors, are points to check in the quarterly report's explanations.

On regulation, the company secured Swiss marketing approval for an ertapenem-based finished product on October 2, 2026, following earlier approvals in the US, the EU, Saudi Arabia, the UAE and Southeast Asia.

CEO Chahn said sales in many countries, including the US and Europe, should lead to higher revenue from global customers over the long term. Whether the approval track record translates into higher orders is cited as the first measure of the new management's results.

The next checkpoints are whether carbapenem shipments recover and whether the customer and regional mix changes in the 2026 annual report.

07

Valuation

PER
11.2×
PBR
0.6×
ROE
5.7%
EPS
₩692
BPS
₩12,532
Dividend per share
₩150

Valuation depends on how earnings are read, because profit is moving sharply from quarter to quarter. A net loss attributable to controlling shareholders in the third quarter of 2026 makes quarterly multiples less meaningful on their own.

Controlling-shareholder profit for the last four quarters totals KRW 7.36 billion, below the KRW 13.7 billion reported for 2024. The price-to-book ratio sits below 1x, which means the market value trades at a discount to book equity.

Total equity of KRW 130.7 billion at year-end 2025 is large relative to recent earnings, so how fast profit recovers will change how the multiples are read. Operating cash flow of KRW 17 billion in 2025 exceeded controlling-shareholder profit of KRW 11.5 billion, which supports the cash backing of earnings.

A useful reference point is comparing the 2026 quarterly operating margins with the 18–20% annual margins of 2024 and 2025. The cash dividend approved at the March 2026 shareholders' meeting is a shareholder-return item to track.

The largest shareholder's 45.19% stake means a limited share of the stock trades freely, which is a structural feature of the shareholder base.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Regulatory approvals accumulating

In 2025 a carbapenem combination antibiotic using the company's ingredient was approved by the FDA and the European Union, and in 2026 approvals were added in Canada, Argentina and three Balkan countries. In October 2026 a finished product using its ertapenem ingredient also received Swiss marketing approval.

The company said sales become possible in major markets and that revenue from global customers should rise over the long term.

Track record of high profitability

The operating margin rose from 4.8% in 2022 to 20.1% in 2024 and held at 18.3% in 2025. In the second quarter of 2026 the company returned to profit with revenue of KRW 23.4 billion and operating profit of KRW 6.29 billion. The bullish argument is that quarterly profit could recover if production returns to normal levels.

Balance sheet headroom

At the end of 2025 the debt ratio was 10.0% and total liabilities were KRW 13 billion. Operating cash flow reached KRW 17 billion in 2025, above controlling-shareholder profit of KRW 11.5 billion. A cash dividend was resolved at the March 2026 general shareholders' meeting.

09

Bear factors

Concentration by region and customer

Exports were 99.95% of 2025 revenue, Europe accounted for 87.37%, and sales tied to ACS Dobfar made up 87.4%. The high share of carbapenem products ties results to one antibiotic class. A policy or demand change in a single customer or region passes directly into revenue.

Low utilization and weaker quarterly profit

First-quarter 2026 utilization stayed in the 60% range, at 62.7% in Chungju and 62.9% in Daeso. Third-quarter 2026 operating profit was KRW 1.1 billion, down 71.8% year on year, and the company posted a controlling-shareholder net loss of KRW 774 million. Revenue in 2025 also fell 9.5% from the prior year.

Price competition and raw-material risk

The annual report cited excessive price competition and dumping by Chinese manufacturers as a cause of the 2025 decline. An explosion at an overseas intermediate-material supplier, which unsettled raw-material supply, was also named as a burden on profitability. If price competition persists, the pace of margin recovery could be constrained.

10

Risk factors

Customer and regional concentration

Because most revenue comes from European regulated markets and a few customers, a sales slowdown or contract change at one buyer quickly affects volumes. Approvals in new countries are accumulating, but converting them into new customers may take time. The annual report is the baseline for tracking changes in customer mix.

Production and raw-material supply

A roughly 40-day production gap at the end of 2025 and equipment maintenance in the first quarter of 2026 kept utilization in the 60% range. Supplier accidents are external shocks, so how far supply sources are diversified is critical. The timing of plant normalization and the utilization level set the premise for upcoming quarterly results.

Drug pricing, exchange rates and regulation

An April 2026 press report attributed a joint earnings decline among API makers to drug price reform and a strong-dollar environment. Because nearly all sales are exports, exchange-rate and pricing changes flow directly into revenue and margins. Delays in regulatory approvals or changes to existing approval conditions would affect plans for new sales.

11

What to watch next

  1. From December 2026 (ad hoc disclosures)

    Check new national approvals and contract disclosures with global customers. This shows whether the approval track record leads to higher volumes.

  2. Late March 2027 (around the 2026 annual report deadline)

    Review the 2026 full-year operating margin, fourth-quarter profit, and changes in regional and customer mix in the annual report. Compare with the 18.3% operating margin of 2025.

  3. Around the March 2027 general shareholders' meeting

    Check whether a cash dividend for fiscal 2026 is resolved and whether the board composition changes.

  4. Mid-May 2027 (Q1 2027 quarterly report deadline)

    Check whether utilization moves above the 60% range and the first-quarter operating margin. Compare with the KRW 1.1 billion operating loss in the first quarter of 2026.

12

Overall view

High Tech Pharm is a KOSDAQ-listed maker of carbapenem antibiotic APIs that sells mainly to overseas customers, with most revenue coming from regulated markets such as Europe. Since 2022, operating profit and controlling-shareholder profit peaked in 2024 and declined in 2025.

In 2026 the company posted an operating loss in the first quarter and a controlling-shareholder net loss in the third quarter, weakening the earnings trend.

The company attributed the first-quarter loss to temporary items including equipment maintenance and stock-compensation costs, and returned to profit in the second quarter. Because operating profit fell again in the third quarter, whether temporary factors fully explain the trend needs confirmation.

On the positive side, approvals in regulated markets such as the US, the EU and Switzerland are accumulating, and the debt ratio of 10.0% reflects a low-leverage balance sheet.

On the negative side, concentration with 99.95% exports and 87.37% European sales, utilization in the 60% range, and dumping by Chinese manufacturers remain sources of earnings volatility.

The next checkpoints are the operating margin in the 2026 annual report, utilization in the first quarter of 2027, and whether new approvals translate into sales volume.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. dailypharm.com
  2. comp.fnguide.com
  3. dailypharm.com
  4. dailypharm.com
  5. sujuradar.com
  6. vegannews.co.kr
  7. htpharm.com
  8. creditnews.kr
  9. news.nate.com
  10. m.news.nate.com
  11. newspim.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis